|| Checking for direct PDF access through Ovid
Background: Growing evidence links sleep quality to CVD risk, and inflammation may be one mechanism by which sleep affects CVD outcomes. We sought to investigate the association of sleep quality and duration with inflammation in a community based cohort.Methods: We administered the Pittsburgh Sleep Quality Index (PSQI) to 525 participants (age 51±9 years, 47% African American, 61% female) enrolled in the Morehouse-Emory Partnership to Eliminate Cardiovascular Health Disparities (META-Health) study. Poor sleep quality was defined as a total PSQI score ≥6 (median). Sleep duration was derived from the PSQI, and categorized into <6, 6-8.9, and ≥9 hours. Levels of fibrinogen, interleukin (IL)-6, and C-reactive protein (CRP) were examined as continuous values. Analyses were adjusted for age, gender, race, smoking, hypertension, diabetes, waist circumference, blood pressure, glucose, and lipid profile.Results: Participants with poor sleep quality had higher levels of fibrinogen, IL-6, and CRP (all p≤0.01) than participants with good sleep quality. One-way analysis of variance testing revealed that levels of fibrinogen (p<0.001), IL-6 (p=0.008), and CRP (p=0.001) differed across the 3 categories of sleep duration (Figure 1). Post-hoc comparisons indicated that sleep duration of 6-8.9 hours was associated with significantly lower levels of mean fibrinogen (3.5±0.4 vs. 3.7±0.4 g/L, p<0.001), and median IL-6 (0.8 [0.6,1.1] vs. 1.0 [0.7,1.2] pg/mL, p=0.003) and CRP (1.6 [1.1,2.3] vs. 2.0 [1.4,3.3] mg/L, p<0.001) compared to sleep duration <6 hours. Comparisons between sleep durations 6-8.9 and ≥9 hours were not statistically significant.Conclusion: Poor sleep quality, and short sleep durations are associated with higher levels of inflammation. Normalizing sleep quality and duration may be a therapeutic target for improving CVD risk.